{"url_path":"/sec/celu/8-k/2026-06-25/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1752828/0001493152-26-030199-index.html","accession_number":"0001493152-26-030199","cik":"0001752828","ticker":"CELU","issuer_name":"Celularity Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1752828/0001493152-26-030199-index.html","primary_entity_key":"0001752828","primary_entity_name":"Celularity Inc"},"word_count":383,"has_tables":true,"body_markdown":"**Item\n5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of\nCertain Officers.**\n\n \n\nAppointment\nof Certain Officers\n\n \n\nOn\nJune 19, 2026, the Company’s Board of Directors (the “Board”) appointed Steven N. Gordon, Esq. as the Company’s\nChief Operating and Administrative Officer. Mr. Gordon is an entrepreneur, investor and business executive with significant experience\nin corporate finance, operations, strategic development and capital formation in the biotechnology sector. Mr. Gordon has been actively\ninvolved in the Company’s financing, restructuring and strategic initiatives and has served as the Company’s EVP, Business\nAffairs since January 2026.\n\n \n\nEffective\nJune 19, 2026, the Board also appointed K. Harold Fletcher, Esq. as the Company’s Chief Legal and Strategy Officer and Corporate\nSecretary. Mr. Fletcher has substantial experience in corporate governance, securities law, strategic transactions, financings, healthcare\ncompliance and public company matters. Prior to his appointment, Mr. Fletcher served as the Company’s EVP, Legal and Strategy since\nJanuary 2026 and previously served as the Company’s General Counsel, Chief Compliance Officer and Assistant Corporate Secretary.\n\n \n\nThere\nare no family relationships between either Mr. Gordon or Mr. Fletcher and any director or executive officer of the Company. There are\nno arrangements or understandings between either officer and any other person pursuant to which such officer was appointed, other than\narrangements with the Company. Any compensation arrangements for Mr. Gordon and Mr. Fletcher will be disclosed, if required, in subsequent\nfilings.\n\n \n\nElection\nof Director\n\n \n\nEffective\nJune 19, 2026, the Board appointed Mr. Gordon as a member of the Board. Mr. Gordon will serve as a director until his successor is duly\nelected and qualified or until his earlier resignation, death or removal.\n\n \n\nThere\nare no arrangements or understandings between Mr. Gordon and any other person pursuant to which he was appointed as a director, other\nthan arrangements with the Company. There are no transactions involving Mr. Gordon requiring disclosure under Item 404(a) of Regulation\nS-K, except as may be disclosed in subsequent filings.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**CELULARITY\nINC**.\n\nDated:\nJune 25, 2026\n \n\n \nBy:\n*/s/\nRobert J. Hariri*\n\n \nName:\nRobert\nJ. Hariri, MD, PhD\n\n \nTitle:\nChairman\nand Chief Executive Officer"}